Overexpression of Aurora B is linked to poor prognosis in various malignancies; however, its prognostic role remains debatable. Conducting a meta-analysis is essential to reach a definitive conclusion.
Methods:
Various databases were searched. Aurora B protein expression was assessed for prognostic significance using pooled hazard ratio (HR) with a 95% confidence interval (CI). Meta-regression and subgroup analysis identified the source of heterogeneity.
Results:
The study comprised 1384 cancer patients from 10 articles. The result with multivariate data (pooled HR=1.18, 95% CI= 0.71-1.95, p=0.52, I²=83%) and univariate data (pooled HR=1.81, 95% CI=0.92, 3.57, p=0.09, I2=89%) showed that increased Aurora B expression was not linked with poor overall survival (OS). Subgroup analysis showed that sample size, follow-up time, cut-off value, non-Chinese patients, antibody source were not associated with unfavorable OS.
Conclusions:
Aurora B expression could not be used as a prognostic marker in cancer.
JokhadzeNDasADizonDS. Global Cancer Statistics: A Healthy Population Relies On. CA Cancer J Clin2024; 74(3).
2.
WeiskirchenR.Intratumor heterogeneity, variability and plasticity: questioning the current concepts in classification and treatment of hepatocellular carcinoma. Hepatobiliary Surg Nutr2016; 5: 183.
3.
ZhuWLévy-LeducCTernèsN.Identification of prognostic and predictive biomarkers in high-dimensional data with PPLasso. BMC Bioinformatics2023; 24: 25.
4.
ZhuC-QTsaoM-S.Prognostic markers in lung cancer: is it ready for prime time?Transl Lung Cancer Res2014; 3: 2729.
5.
ZeitlinSGShelbyRDSullivanKF.CENP-A is phosphorylated by Aurora B kinase and plays an unexpected role in completion of cytokinesis. J Cell Biol2001; 155: 1147–1158.
6.
MaPHaoYWangW, et al. AURKB activates EMT through PI3K/AKT signaling axis to promote ICC progression. Discov Oncol2023; 14: 102.
7.
BorahNAReddyMM.Aurora kinase B inhibition: a potential therapeutic strategy for cancer. Molecules2021; 26: 1981.
8.
OtaTSutoSKatayamaH, et al. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res2002; 62: 5168–5177.
9.
WangCChenJCaoW, et al. Aurora-B and HDAC synergistically regulate survival and proliferation of lymphoma cell via AKT, mTOR and Notch pathways. Eur J Pharmacol2016; 779: 1–7.
10.
Vargo-GogolaTRosenJM.Modelling breast cancer: one size does not fit all. Nat Rev Cancer2007; 7: 659–672.
11.
ShahETMolloyCGoughM, et al. Inhibition of Aurora B kinase (AURKB) enhances the effectiveness of 5-fluorouracil chemotherapy against colorectal cancer cells. Br J Cancer2024; 130: 1196-1205.
12.
ZhangJLinXWuL, et al. Aurora B induces epithelial–mesenchymal transition by stabilizing Snail1 to promote basal-like breast cancer metastasis. Oncogene2020; 39: 2550–2567.
13.
ZengWFNavaratneKPraysonRA, et al. Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme. J Clin Pathol2007; 60: 218–221.
14.
VischioniBOudejansJJVosW, et al. Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol Cancer Ther2006; 5: 2905–2913.
15.
YangYShengYSunD, et al. AURKB promotes tumorigenesis and carboplatin resistance by regulating the ERK pathway in neuroblastoma cells. Int J Neurosci2023; 133: 1224–1232.
16.
ZhaoHWangYYangZ, et al. High expression of aurora kinase B predicts poor prognosis in hepatocellular carcinoma after curative surgery and its effects on the tumor microenvironment. Ann Transl Med2022; 10: 1168–1168.
17.
AbudureyimuKGuoYMaimaitiY, et al. Aurora kinase B is an exceptional prognostic biomarker for invasive ductal carcinoma and may be a new target for endocrine therapy-resistant breast cancer. Int J Clin Exp Med2017; 10: 3337–3344.
18.
EnjojiMIidaSSugitaH, et al. BubR1 and AURKB overexpression are associated with a favorable prognosis in gastric cancer. Mol Med Rep2009; 2: 589–596.
19.
MendiolaMBarriusoJMariño-EnríquezA, et al. Aurora kinases as prognostic biomarkers in ovarian carcinoma. Hum Pathol2009; 40: 631–638.
20.
Burum-AuensenEDeangelisPMSchjølbergAR, et al. Reduced level of the spindle checkpoint protein BUB1B is associated. Cell Prolif2008; 41: 645–659.
21.
PageMJMcKenzieJEBossuytPM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ2021; 372: n71.
22.
ChenYJChenCMTwuNF, et al. Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients. Virchows Arch2009; 455: 431–440.
23.
LiangXWangDWangY, et al. Expression of Aurora Kinase A and B in chondrosarcoma and its relationship with the prognosis. Diagn Pathol2012; 7: 1.
24.
ErpolatOPGocunPUAkmansuM, et al. High expression of nuclear survivin and Aurora B predicts poor overall survival in patients with head and neck squamous cell cancer. Strahlentherapie und Onkol2012; 188: 248–254.
25.
HuangPYLiYLuoDH, et al. Expression von Aurora-B und FOXM1 prognostizieren schlechtes Überleben bei Patienten mit nasopharyngealem Karzinom. Strahlentherapie und Onkol2015; 191: 649–655.
26.
XiaRChenSChenY, et al. Achromosomal passenger complex protein signature model predicts poor prognosis for non-small-cell lung cancer. Onco Targets Ther2015; 8: 721–726.
27.
LiuFWangGWangX, et al. Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinoma. Oncotarget2017; 8: 27953–27965.
28.
KohHMJangBGHyunCL, et al. Prognostic value of NOX4 expression in cancer patients: a systematic review and meta-analysis. Dis Markers2022; 2022: 8567642.
29.
WangSWuJShenH, et al. The prognostic value of IDO expression in solid tumors: a systematic review and meta-analysis. BMC Cancer2020; 20: 471.
30.
PengZLinHZhouK, et al. Predictive value of pretreatment PD-L1 expression in EGFR-mutant non-small cell lung cancer: a meta-analysis. World J Surg Oncol2021; 19: 145.
31.
HuangLChenLWangY, et al. Nestin expression and the survival of patients with digestive tract cancers: a systematic review and meta-analysis. Turkish J Gastroenterol2023; 34: 902–910.
32.
AhmedAShamsiAMohammadT, et al. Aurora B kinase: a potential drug target for cancer therapy. J Cancer Res Clin Oncol2021; 147: 2187–2198.
33.
KovacsAHZhaoDHouJ.Aurora B inhibitors as cancer therapeutics. Molecules2023; 28:8.
34.
TangAGaoKChuL, et al. Aurora kinases: novel therapy targets in cancers. Oncotarget2017; 8: 23937–23954.
35.
SubramaniyanBKumarVMathanG.Effect of sodium salt of Butrin, a novel compound isolated from Butea monosperma flowers on suppressing the expression of SIRT1 and Aurora B kinase-mediated apoptosis in colorectal cancer cells. Biomed Pharmacother2017; 90: 402–413.
36.
GarlapatiCJoshiSBhattaraiS, et al. PLK1 and AURKB phosphorylate survivin differentially to affect proliferation in racially distinct triple-negative breast cancer. Cell Death Dis2023; 14: 12.
37.
ZhuLBJiangJZhuXP, et al. Knockdown of Aurora-B inhibits osteosarcoma cell invasion and migration via modulating PI3K/Akt/NF-κB signaling pathway. Int J Clin Exp Pathol2014; 7: 3984.
38.
WangZYuZWangG, et al. AURKB promotes the metastasis of gastric cancer, possibly by inducing EMT. Cancer Manag Res2020; 12: 6947–6958.
39.
YuJZhouJXuF, et al. High expression of Aurora-B is correlated with poor prognosis and drug resistance in non-small cell lung cancer. Int J Biol Markers2018; 33: 215–221.
40.
LiLJiangPHuW, et al. AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2. J Transl Med2024; 22: 295.
41.
GullyCPZhangFChenJ, et al. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol Cancer2010; 9: 1–13.
42.
AiharaATanakaSYasenM, et al. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J Hepatol2010; 52: 63–71.
43.
PortellaGPassaroCChieffiP.Aurora B: a new prognostic marker and therapeutic target in cancer. Curr Med Chem2011; 18: 482–496.
44.
BorgesKSMorenoDAMartinelliCEJr, et al. Spindle assembly checkpoint gene expression in childhood adrenocortical tumors (ACT): overexpression of Aurora kinases A and B is associated with a poor prognosis. Pediatr Blood Cancer2013; 60: 1809–1816.
45.
KuraiMShiozawaTShihHC, et al. Expression of Aurora kinases A and B in normal, hyperplastic, and malignant human endometrium: Aurora B as a predictor for poor prognosis in endometrial carcinoma. Hum Pathol2005; 36: 1281–1288.
46.
García-FernándezEDe DiegoJICollantes-BellidoE, et al. Aurora B kinase expression in laryngeal squamous cell carcinoma and its prognostic implications. Histopathology2011; 58: 368–376.
47.
BaldiniETuccilliCPrinziN, et al. Deregulated expression of Aurora kinases is not a prognostic biomarker in papillary thyroid cancer patients. PLoS One2015; 10: e0121514.
48.
NadlerYCampRLSchwartzC, et al. Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clin Cancer Res2008; 14: 4455–4462.
49.
HuLKongFPanY.Prognostic and clinicopathological significance of S100A14 expression in cancer patients: A meta-analysis. Medicine (Baltimore)2019; 98: e16356.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
